Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
KADCYLA (ado-trastuzumb emtansine)
First FDA approved antibody-drug conjugate (ADC) for HER2-positive metastatic breast cancer
TO VIEW PI and LEARN MORE CLICK HERE